The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.
 
David Cescon
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Exact Sciences; GenomeRx; Gilead Sciences; GlaxoSmithKline; Lilly; Merck; Novartis; Pfizer; Roche/Genentech; SAGA Diagnostics
Research Funding - AstraZeneca (Inst); GenomeRx (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Guardant Health (Inst); Inivata (Inst); Knight Therapeutics (Inst); Merck (Inst); PearBio (Inst); Pfizer (Inst); ProteinQure (Inst); RayzeBio (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent (US62/675,228) for methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene.
(OPTIONAL) Uncompensated Relationships - Inivata/NeoGenomics
 
Tiffany Traina
Consulting or Advisory Role - Aktis Oncology; AstraZeneca; BioNTech SE; Bristol Myers Squibb; Corcept Therapeutics; Daiichi Sankyo; Ellipses Pharma; Exact Sciences; Genentech/Roche; Gilead Sciences; Merck; Pfizer; Stemline Therapeutics; Tersera; Veracyte
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Pfizer (Inst)
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Bayer; Bayer; Boehringer Ingelheim; Celgene; Celgene; Eisai; Genentech (Inst); Gilead Sciences Hong Kong; Merck; Novartis; Oncogenex (Inst); Oncogenex (Inst); Pfizer; Puma Biotechnology; Roche; Sanofi; Stemline Therapeutics
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)
Travel, Accommodations, Expenses - ESMO; SABS
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MAJ3 Capital
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung; Steamline Therapeutics; Zuellig Pharma
Consulting or Advisory Role - Abbvie; AstraZeneca; Athenex; Bioasis; Biocon; Bioinvent; BioNTech SE; Bliss Biopharmaceutical; Boehringer Ingelheim; Bridgebio; Celgene; Cellestia Biotech; Circle Pharma; Clovis Oncology; Daiichi Sankyo; Delcath Systems; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; Hexagon Bio; HiberCell; Jazz Pharmaceuticals; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Relay Therapeutics; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Merck Sharp&Dhome; Novartis; Pfizer; Roche; Steamline Therapeutics
 
Zhimin Shao
No Relationships to Disclose
 
Shigehira Saji
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Kyowa Kirin; Lilly; MSD; Myriad Genetics; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Kyowa Kirin; Lilly; MSD; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
 
Kyung Hae Jung
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bixink; Celgene; Daewoong Pharmaceutical; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Eisai; Eisai; Everest Medicine; Gilead Sciences; ImmuneOncia; Merck; MSD; Novartis; Novartis; Novartis; Novartis; Pfizer; Roche; Roche; Takeda
 
Thomas Bachelot
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Lilly; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; pfizer; Roche
 
Shouman Wang
No Relationships to Disclose
 
Emilio Ramírez
No Relationships to Disclose
 
Gul Basaran
Consulting or Advisory Role - Astra Zeneca, Daiichi-Sankyo, Gilead, Roche
Research Funding - Roche
Other Relationship - Novartis Steering Committee
 
Yee Soo Chae
No Relationships to Disclose
 
Agostina Stradella
Consulting or Advisory Role - Astra Zeneca, Boehringer Ingelheim, Novartis, Seagen, Gilead
Speakers' Bureau - Daiichi-Sankyo, Novartis, MSD, AstraZeneca
Travel, Accommodations, Expenses - Eisai, Novartis, Pfizer, Gilead, MSD
 
Rofhiwa Mathiba
No Relationships to Disclose
 
Shin-Cheh Chen
No Relationships to Disclose
 
Nicola Battelli
Honoraria - AstraZeneca, Daiichi Sankyo, Eli Lilly, Genetic, Menarini, Novartis, Pfizer, Roche - Invited Speaker
 
Naoki Niikura
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; MSD; Novartis; Pfizer
Research Funding - Chugai Pharma; Daiichi Sankyo; Eisai; Mochida Pharmaceutical Co. Ltd. (Inst); Novartis (Inst); Pfizer
 
Kechen Zhao
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Micah Maxwell
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Rebecca Dent
Honoraria - AstraZeneca; BioNTech SE; Daiichi Sankyo/Astra Zeneca; DKSH; Eisai; Gilead Sciences; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; Gilead Sciences; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; MSD; Novartis; Pfizer; Roche